A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The 2016 Olympic medals were the largest diameter of any medals presented at the Olympics up to this point. The golds were purer than any presented at all preceding Olympics. The silvers were made from recycling mirrors, solder, and X-ray plates. Just under half of the copper used in the bronze medals was recycled from normal operations at the Brazilian Mint. The reverse of the medals features Nike, the Greek goddess of victory.
=== Starbucks card and loyalty program === In May 2008, a loyalty program was introduced for registered users of the Starbucks Card (previously simply a gift card) offering perks such as free Wi-Fi Internet access, no charge for soy milk and flavored syrups, and free refills on brewed drip coffee, iced coffee, or tea. Each time a customer purchases a drink, they earn stars if they present their rewards card or scan their card from the mobile app. Eventually, these stars accumulate to allow customers to redeem for perks such as free drinks, free add-ins, free bakery items or selected merchandise. In 2009, Starbucks began beta testing its mobile app for the Starbucks card, a stored value system in which consumers access pre-paid funds to purchase products at Starbucks. Starbucks released its complete mobile platform in January 2011. By December 2011, the number of mobile transactions exceeded 26 million.
== Applications == For the past 30 years, isothermal titration calorimetry has been used in a wide array of fields, ranging from metal binding studies to drug discovery, and nanomaterials research. In the old days, this technique was used to determine fundamental thermodynamic values for basic small molecular interactions. In recent years, ITC has been used in more industrially applicable areas, such as drug discovery and testing synthetic materials. Although it is still heavily used in fundamental chemistry, the trend has shifted over to the biological side, where label-free and buffer independent values are relatively harder to achieve.
Sources: en.wikipedia.org
=== Secondary cold agglutinin disease === Secondary cold agglutinin syndrome occurs when autoantibodies bind to red blood cells, rendering them subject to attack by the complement system. It is a result of an underlying condition potentially associated with either monoclonal cold-reacting autoantibodies or polyclonal cold-reacting autoantibodies predominantly caused by infection or lymphoproliferative disorders. In adults, this is typically due to:
=== Neutering status in animals === In veterinary medicine, AMH measurements are used to determine neutering status in male and female dogs and cats. AMH levels can also be used to diagnose cases of ovarian remnant syndrome.
=== Phosphodiesterase 5 inhibitors === Many men who have PE also suffer from erectile dysfunction (ED). Treatment for these patients should consider the drug–drug interaction between dapoxetine and PDE5 inhibitors such as tadalafil (Cialis) or sildenafil (Viagra). In Dresser study (2006), plasma concentration of 24 subjects was obtained. Half of the sample pool were treated with dapoxetine 60 mg plus tadalafil 20 mg; the other half were treated with dapoxetine 60 mg plus sildenafil 100 mg. These plasma samples were then analyzed using liquid chromatography-tandem mass spectrometry. The results showed that dapoxetine does not alter the pharmacokinetics of tadalafil or sildenafil.
=== 1978 === January 29: The Chadian–Libyan conflict begins over the Aouzou Strip. March 15: The Ogaden War ends with a cease-fire. March 16: Italian Prime Minister Aldo Moro is kidnapped in Rome by a far-left extremist terrorist group called the Red Brigades. His body would be found on the 9th of May after 55 days of captivity. April 27: President of Afghanistan Sardar Mohammed Daoud's government is overthrown when he is murdered in a coup led by pro-communist rebels. May 11: The second rebellion in the Shaba Province, Zaire occurred. October 1: Tuvalu becomes independent from the UK as a member of the Commonwealth. November 3: Dominica becomes independent from the UK. December 18: Deng Xiaoping announces the reform and opening up of China. December 25: Vietnam invades Cambodia.
Sources: en.wikipedia.org
===== MeSH D08.811.399.325 – cis-trans-isomerases (EC 5.2) ===== MeSH D08.811.399.325.500 – peptidylprolyl isomerase MeSH D08.811.399.325.500.400 – immunophilins MeSH D08.811.399.325.500.400.300 – cyclophilins MeSH D08.811.399.325.500.400.300.500 – cyclophilin A MeSH D08.811.399.325.500.400.700 – tacrolimus binding proteins MeSH D08.811.399.325.500.400.700.500 – tacrolimus binding protein 1a
== Governance == RCB is an institution of international importance in biotechnology, education, training and research. The Board of Governors (BoG), composed of eminent scientists and specialists in the field of biotechnology, representing Government of India and UNESCO are responsible for the governance of the Centre. The Programme Advisory Committee (PAC), composed of experts within India and abroad, provide support and guidance for the centre's education, training and research programmes. On behalf of the Governing body, the Executive Director executes policies and functions of the Centre with the guidance of a duly constituted Executive Committee.
=== Ongoing renewal of the Special Diabetes Program === Breakthrough T1D has been supporting the "Special Diabetes Program" (SDP) for 25 years. The program, which receives over $150 million in federal funding per year, provides resources and support for T1D research in cooperation with the NIH. Breakthrough T1D works with the U.S. Senate Diabetes Caucus to advocate for continued funding of the program, which also benefits Breakthrough T1D's research efforts.
38 Mod 3): Nimitz-class aircraft carrier, Arleigh Burke-class destroyer, Ticonderoga-class cruiser, Oliver Hazard Perry-class frigate, Wasp-class amphibious assault ship, Tarawa-class amphibious assault ship, Whidbey Island-class dock landing ship, Harpers Ferry-class dock landing ship, Austin-class amphibious transport dock, Blue Ridge-class command ship, Cyclone-class patrol ship, Mark VI patrol boat Marine Corps: LAV-25 Coast Guard (Mk. 38 Mod 0, Mk. 38 Mod 2 and Mk. 38 Mod 3): Reliance-class cutter, Hamilton-class cutter, Sentinel-class cutter, Island-class cutter, USCGC Alex Haley, future Heritage-class cutter
In mining, Colombia is the world's largest producer of emerald, and in the production of gold, between 2006 and 2017, the country produced 15 tons per year until 2007, when its production increased significantly, beating the record of 66.1 tons extracted in 2012. In 2017, it extracted 52.2 tons. Currently, the country is among the 25 largest gold producers in the world.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.